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LARP1 post-transcriptionally regulates mTOR and
contributes to cancer progression
MMura1, TG Hopkins1, T Michael1, N Abd-Latip1, J Weir2, E Aboagye3, F Mauri4, C Jameson5, J Sturge3,6, H Gabra1, M Bushell7, AE Willis7,
E Curry1 and SP Blagden1
RNA-binding proteins (RBPs) bind to and post-transcriptionally regulate the stability of mRNAs. La-related protein 1 (LARP1) is a
conserved RBP that interacts with poly-A-binding protein and is known to regulate 5′-terminal oligopyrimidine tract (TOP) mRNA
translation. Here, we show that LARP1 is complexed to 3000 mRNAs enriched for cancer pathways. A prominent member of the
LARP1 interactome is mTOR whose mRNA transcript is stabilized by LARP1. At a functional level, we show that LARP1 promotes cell
migration, invasion, anchorage-independent growth and in vivo tumorigenesis. Furthermore, we show that LARP1 expression is
elevated in epithelial cancers such as cervical and non-small cell lung cancers, where its expression correlates with disease
progression and adverse prognosis, respectively. We therefore conclude that, through the post-transcriptional regulation of genes
such as mTOR within cancer pathways, LARP1 contributes to cancer progression.
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INTRODUCTION
RNA-binding proteins (RBPs) regulate the decay kinetics and
translational efﬁciency of mRNA transcripts by accelerating their
degradation or prolonging their cytoplasmic half-life.1 In this way,
the abundance of mRNAs and their encoded proteins can be
altered in a manner that is independent from gene transcription.
As RBPs are themselves activated by growth factors and cell
signals, this tightly regulated post-transcriptional mechanism
enables the cell to rapidly adjust levels of protein expression in
response to intrinsic and extracellular signals.2,3 In addition, RBPs
can interact with up to thousands of mRNA transcripts, allowing
the coordinated synthesis of multiple proteins involved in a single
physiological function (termed an RNA operon).4 However, when
the expression of an RBP is disrupted, it can potentially disrupt
cellular homeostasis and autonomously drive pathological pro-
cesses by uncoupling the regulation of mRNA stability from cell
signaling cues.5 A protein recently identiﬁed as being an RBP is La-
related protein 1 (LARP1).6 LARP1 belongs to the LARP family,
three members of which: LARP1, LARP3 (or genuine La protein)
and LARP7 have so far been implicated in cancer. An elevated
expression of LARP1 has been shown to correlate with clinical
outcome in hepatocellular carcinoma,7 LARP3 protein expression
is increased in cervical cancer and higher levels have been shown
to correlate with adverse outcome in lung cancer.8,9 In contrast,
LARP7 is a potential tumor suppressor in gastric and cervical
tumors.10,11
LARP1 was ﬁrst identiﬁed in Drosophila melanogaster, where it
was shown to bind poly-A-binding protein (PABP) and was
required for embryonic development and fertility.12 Proteomic
screens conducted in human embryonic cell lines have
subsequently shown that LARP1 contributes to the stability and
translation of 5′-terminal oligopyrimidine tract (TOP) mRNAs
by simultaneously interacting with their 5′-cap components
and their 3′-untranslated regions (UTRs).13,14 TOP mRNAs are
required for ribosome biogenesis and are regulated down-
stream of the mammalian (or mechanistic) target of rapamycin
(mTOR) complex 1 (mTORC1) kinase. The recent discovery that
LARP1 is itself regulated downstream of mTORC1 signaling has
placed it as a key player within the mTOR pathway and as a
regulator of cellular growth and proliferation.14–16 As perturbation
of mTOR signaling is a common occurrence in cancer, we chose
two tumor types: squamous cervical and non-small cell lung
cancers, in which mTOR pathway signaling is frequently disrupted,
to explore the relationship between LARP1 and mTOR.17–19 We
demonstrate that, rather than solely acting downstream of mTOR,
LARP1 also post-transcriptionally regulates mTOR by binding and
stabilizing its encoding mRNA. Moreover, we show that the
regulatory activity of LARP1 is not just conﬁned to mTOR, but that
LARP1 is complexed to many other mRNA transcripts involved in
cancer-related functions. We demonstrate that LARP1 expression
correlates with clinical outcome in cervical and non-small cell lung
cancers and, at functional level, regulates cell migration, invasion,
anchorage-independent and in vivo tumor growth.
RESULTS
LARP1 expression is increased in epithelial cancers and correlates
with clinical variables
We examined the expression of LARP1 across multiple cancers
using a systematic review of datasets in the Oncomine
repository (available at http://www.oncomine.org).20 LARP1-
mRNA expression was increased across almost all epithelial
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malignancies (Supplementary Figure 1a and Supplementary Table
1). Of these, we chose to focus predominantly on cervical (SCC) as
a model system. Cervical SCC not only is associated with aberrant
mTOR19 activation, but also has a clearly deﬁned progression from
pre-malignant cervical intraepithelial neoplasia to established
cancer, characterized by increasing invasiveness. Searching
Oncomine for expression data comparing cancer and non-
cancer samples revealed a single study (n= 45) where tissue from
normal cervix was compared to cervical cancer.10 This demon-
strated signiﬁcantly higher LARP1-mRNA levels in cervical (SCC;
Figure 1a). To validate this, we obtained total RNA from surgical
samples of human cervical SCC and non-cancer cervical tissue
(Imperial College Tissue Bank, London, UK). Real-time PCR
demonstrated that LARP1-mRNA expression was signiﬁcantly
increased in cervical SCC (Figure 1b).
Using immunohistochemistry, we quantiﬁed LARP1 expression
in a tissue microarray comprising tissue cores (n= 83) from normal
cervical epithelium, cervical intraepithelial neoplasia and invasive
cervical SCC. We found signiﬁcant increased levels of LARP1
in cervical intraepithelial neoplasia versus normal epithelium and
cervical SCC versus cervical intraepithelial neoplasia, conﬁrming
that cytoplasmic LARP1 signiﬁcantly correlated with progression
of cervical cancer (Figures 1c and d). In support of this ﬁnding,
publicly available expression data (n= 76) demonstrated that
LARP1 levels signiﬁcantly increased with increasing stage of
invasive cancer21 (Figure 1e).
To validate our ﬁndings, we assessed LARP1 levels in a second
epithelial cancer type in which mTOR is known to be
dysregulated17,18 with a similarly poor clinical outcome. Consistent
with our ﬁndings in cervical SCC, using pooled survival analysis of
Figure 1. LARP1 correlates with clinical variables in cervical cancer. (a) Expression dataset comparing LARP1-mRNA levels in cervical squamous
cell carcinoma (SCC) and non-cancer tissue. (b) Real-time PCR on RNA extracted from non-cancer cervical tissue (n= 4) and cervical SCC (n= 7).
LARP1-mRNA levels relative to 18S ribosomal RNA (P= 0.012, Student’s t-test). (c) LARP1 immunostaining (brown) of normal cervical
epithelium (N12), cervical intraepithelial neoplasia (CIN; N35) and invasive cervical SCC (N36), counterstained with haematoxylin. (d) LARP1
cytoplasmic scores for CIN compared to normal samples (Po0.0001) and in invasive cervical SCC compared to CIN samples (Po0.0001). (e)
Expression dataset showing LARP1 expression in cervical SCC, stratiﬁed according to stage. *P⩽0.05, **P⩽ 0.001 and ***P⩽0.0001.
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expression array data for 1405 non-small cell lung cancer patients
we observed that high LARP1-mRNA expression signiﬁcantly
correlated with adverse prognosis (Supplementary Figure 1b).22
The LARP1 interactome is enriched for multiple pathways involved
in cancer
To further explore the association with LARP1 expression and
outcome we then wished to identify the mRNAs that were in
complex with LARP1. We performed RNA immunoprecipitation
and microarray proﬁling (RIP-Chip) using anti-LARP1 antibody in
HeLa cells (Supplementary Figure 2a). This approach has been
shown to enrich for stable and functionally signiﬁcant
interactions.23 A robust and reproducible list of LARP1-mRNA
associations was obtained from four individual experiments,
analyzed in duplicate, with the highest density of transcript
interaction within a signiﬁcant threshold (P= 1× 10− 4; Figure 2a).
Figure 2. LARP1 exists in complex with mRNAs. (a) Histogram demonstrating relative transcript density across signiﬁcance thresholds for
LARP1-IP-enriched mRNAs (red line, P= 1 × 10− 4). (b) RIP-Chip validation by qRT–PCR showing fold enrichment of selected target mRNAs
immunoprecipitated with LARP1 antibody, normalized to immunoprecipitation with IgG isotype control. Experiments were performed ⩾ 3
times. Data are mean± s.e.m. *P⩽0.05 and **P⩽0.001.
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We named these the ‘LARP1 interactome’ (Supplementary Table
2). Functional enrichment analysis of transcripts revealed associa-
tions with cancer-related pathways. As well as those controlling
extracellular matrix receptor interactions, regulation of the actin
cytoskeleton, focal adhesion, PI3K, MAPK, VEGF signaling, we
discovered members of the mTOR signaling cascade within the
LARP1 interactome (Supplementary Table 3).
To validate these ﬁndings, we selected seven mRNA targets from
within the LARP1 interactome based on their P-values: AKT1, AKT2
and MAPK11 were highly ranked, while MAPK12, mTOR and Twist-1
were middle to bottom ranked. As a negative control, we selected
MAPK14 which was absent from the interactome. Real-time PCR
(RT–PCR), performed using RNA immunoprecipitated with LARP1
antibody versus IgG isotype control, conﬁrmed that all interactome
mRNAs including mTOR were LARP1 bound (Figure 2b).
LARP1 affects mTOR transcript stability
To further investigate our ﬁnding of mTOR within the interactome,
we explored the effect of LARP1 on mTOR transcript stability by
quantitating mRNA levels after drug inhibition of de novo RNA
transcription. Forty-eight hours after LARP1 knockdown with two
pooled siRNA sequences (Figure 3a) cells were treated with
actinomycin-D. Total RNA was extracted and relative expression
quantiﬁed by RT–qPCR. Two hours following drug treatment,
LARP1-mRNA levels in control siRNA-transfected samples
decreased by 50%, while in cells transfected with LARP1 siRNA
the total mRNA level was constantly decreased by 480%.
Interestingly, mTOR mRNA appeared to be stable and did not
decrease during the time-course treatment with actinomycin-D,
an effect that has been observed previously24,25 (Figure 3b). In
contrast, LARP1-depleted cells treated with actinomycin-D for 4 h
displayed a signiﬁcant decrease in mTOR mRNA (Figure 3b). We
then evaluated the effect of LARP1 on candidates that interact
with high efﬁciency, such as MAPK12 and TWIST1. No signiﬁcant
difference was observed during the time course of the experiment
(0–4 h; Supplementary Figures S3a and b), indicating that LARP1
has a neutral impact on the stability of some of its interactome
targets. mRNA levels of MAPK14, which was absent from the
Figure 3. LARP1 regulate the stability of mTOR mRNA. (a) Western blot showing LARP1 knockdown with pooled siRNA. HSP60 was used as
loading control. (b) Real-time PCR following transcription inhibition by actinomycin-D treatment in HeLa cells transfected with two pooled
LARP1 siRNA or control siRNA. Fold changes relative to 18S, normalized to untreated control. (c) Luciferase production in HeLa cells
transfected with ﬁreﬂy-luciferase reporter construct containing mTOR 3′UTR sequence normalized to the relative control plasmid (bottom
panel: representation of the constructs used) in HeLa cells previously transfected with pooled siRNA to LARP1 or non-targeting siRNA.
(d) Luciferase production in HeLa cells transfected with a renilla-luciferase reporter construct containing mTOR 5′UTR sequence normalized to
the relative control plasmid (bottom panel: representation of constructs used) in HeLa cells previously transfected with pooled siRNA to LARP1
or non-targeting siRNA. Experiments were performed ⩾ 3 times. Data are mean± s.e.m. *P⩽0.05 and **P⩽0.001.
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Figure 4. Depletion of LARP1 alters protein expression of interactome components, with wider effects on mTOR signaling pathway. (a) Level of
LARP1 in HeLa cells transfected with control siRNA and two independent pooled siRNA sequences (siLARP1-1 and siLARP1-2). HSP60 was used
as loading control. (b) Reverse-phase protein array after LARP1 knockdown (data normalized to control siRNA) shows altered expression of
protein products of corresponding mRNAs identiﬁed as existing in complex with LARP1. (c) Change in protein expression and
phosphorylation of mTOR signaling pathway components after LARP1 knockdown (data normalized to control siRNA). Experiments were
performed ⩾ 3 times. Data are mean± s.e.m.
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LARP1 interactome, decreased by 50% following treatment with
actinomycin-D, but no signiﬁcant difference between LARP1-
depleted and control cells was observed during the time course of
the experiment (0–4 h; Figure 3b). These ﬁndings indicate that
LARP1 is required to maintain the stability of mTOR transcripts.
UTRs of mRNAs carry elements responsible for their stability.26
To investigate the effect of LARP1 on mTOR transcript stability, we
analyzed the effect of LARP1 knockdown on mTOR 3′UTR
luciferase-reporter construct and relative control. After LARP1
depletion, a signiﬁcant decrease (24.3%) in ﬁreﬂy-luciferase
activity was observed for the mTOR 3′UTR construct compared
to non-targeting siRNA control (Figure 3c). We then investigated
the effect of LARP1 knockdown on mTOR 5′UTR using a construct
containing the mTOR 5′UTR sequence and relative control. In
contrast to the 3′UTR experiment, no signiﬁcant difference was
observed in the 5′-renilla-luciferase activity between LARP1
knockdown and non-targeting control (Figure 3d). This suggests
that LARP1 effect on the stability of mTOR transcripts is controlled
via elements contained within its 3′UTR.
Protein expression of LARP1-interactome targets is LARP1
dependent
Having demonstrated that LARP1 has an effect on the stability of
mTOR mRNA, we wished to quantitate the effect of LARP1
knockdown (Figure 3a) on the expression of mTOR protein and
other protein components of the mTOR signaling cascade. To do
this, we used a standardized, high-throughput and validated
reverse-phase protein array, representing 138 proteins and 44
phosphoproteins found to be dysregulated in cancer. Of the 45
protein targets on the reverse-phase protein array identiﬁed as part
of the full LARP1 interactome 44% were altered after LARP1
knockdown (Figure 4b). Corresponding with its effect on mTOR
mRNA, we conﬁrmed that knockdown of LARP1 resulted in
reduced mTOR protein expression as well as reduced expression
of a number of other proteins and phosphoproteins within the
mTOR cascade, such as P-mTOR-S2448, RAPTOR, p-RPS6-S235/236,
pRPS6-S240/244 and p90RSK (Figure 4c). Tuberin (TSC2) a negative
regulator of mTORC1/2 decreased on LARP1 knockdown, although
TCS1 showed the opposite trend, perhaps altering the stability of
the TSC1/TSC2 complex. Of interest, RICTOR, a component of the
mTORC2, was increased after LARP1 knockdown.
To further validate the role of LARP1 in regulating mTOR, we
performed and quantiﬁed western blots of mTOR protein, and
downstream components of the mTORC1 signaling cascade in
HeLa and PC9 cell lines (Figures 5a and b and Supplementary
Figures S4a and b). In both lines, knockdown of LARP1 with two
independent siRNAs resulted in reduction of mTOR protein,
phosphorylated RPS6-S240/244 and 4E-BP1-T37/46. In contrast,
LARP1 knockdown did not alter levels of total RPS6 or total 4E-BP1,
the latter showing a moderate decrease in HeLa cells. Our ﬁndings
conﬁrm that, by positively regulating mTOR transcript stability,
LARP1 affects the expression of a number of downstream mTOR
signaling pathway components.
LARP1 regulates components distinct from the mTOR pathway
By reverse-phase protein array, we identiﬁed additional targets
whose protein expression was altered by LARP1 knockdown
beyond the known interactome targets (Supplementary Figures 5a
and b). As LARP1 exists in complex with several transcripts
encoding transcription factors, kinases and regulatory proteins,
this indirect effect was not unexpected, and supports a general
pro-oncogenic role for LARP1. Our protein screen demonstrated
that LARP1 positively regulates anti-apoptotic factors (B Cell
lymphoma 2 (BCL2) and BCL2-associated X protein (BAX)), growth
factor receptors/adapters (epidermal growth factor receptor
(EGFR), vascular endothelial growth factor receptor (VEGFR) and
GRB2-associated binding protein (GAB)), focal adhesion (paxillin),
epithelial-mesenchymal transition EMT effectors (β-catenin) and
transcription factors (Y box binding protein 1 (YB1), tafazzin (TAZ)
and small body size/mothers against decapentaplegic 3 (SMAD3)).
These data suggest that the pro-oncogenic phenotype driven by
LARP1 can be caused by the simultaneous aberration of multiple
signaling pathways. Proteins whose expressions are unchanged
after LARP1 knockdown are summarized in Supplementary Table
S4.
LARP1 promotes cell migration and invasion
As the mTOR pathway is known to be a key effector of invasion
and migration we wished to explore the functional effect of
altered LARP1 expression on these cellular processes.27 First, we
performed a scratch repair assay using HeLa and PC9 cells
transfected with either full-length LARP1 (pTrex-LARP1) or a
control vector (pTrex-LacZ; Supplementary Figures 6a and 7a).
Overexpression of LARP1 signiﬁcantly enhanced cell motility, with
LARP1-overexpressing HeLa and PC9 cells migrating 37 and 40%
faster, respectively, than controls (Supplementary Figures S6b and
7b). We then showed, using Transwell Matrigel invasion assays (BD
Biosciences, Franklin Lakes, NJ, USA), that LARP1 overexpression
signiﬁcantly enhanced the invasive capabilities of HeLa cells
(Figure 6a). A more pronounced effect was seen after LARP1
knockdown, with an 85% reduction in cell invasion (Figure 6b).
Invasion assays performed in PC9 cells after LARP1 knockdown
also showed a signiﬁcant decrease in the number of invasive cells
(Supplementary Figure S7c). These results indicate that the
disruption of LARP1 expression signiﬁcantly alters cancer cell
invasion. There was no signiﬁcant difference in viability or
proliferative ability detected between in vitro cell populations,
either for overexpression or knockdown in either PC9
(Supplementary Figures 7d and e) or HeLa cells during the time
course of the experiments (Supplementary Figures S8a–c).
LARP1 enhances spherosome formation
To investigate the effect of LARP1 on cell survival in anchorage-
independent conditions, we then cultured LARP1-overexpressing
cells in ultra-low attachment plates. Under these conditions, single
cells form ﬂoating colonies termed spherosomes. LARP1 over-
expression signiﬁcantly increased both the total number of
Figure 5. LARP1 knockdown decreases mTOR protein level and its
downstream targets P-RPS6 and P-4EBP in HeLa and PC9 cell lines.
Western blotting analysis of LARP1 in HeLa (a) and PC9 (b) cell lines
after LARP1 knockdown using two independent siRNA oligos
showing decrease in expression of mTOR, P-4EBP and P-RPS6, but
not total RPS6 ribosomal protein. Total 4EBP showed a moderate
decrease in HeLa cells. HSP60 was used as a loading control.
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spherosomes formed (Figure 6c) and the number of viable
colonies identiﬁed when spherosomes were dissociated to a
single-cell suspension and re-plated under adherent conditions
(Figure 6d).
LARP1 promotes tumor growth in vivo
To investigate whether LARP1 regulates tumorigenicity in vivo we
assessed the tumor-forming ability of control and LARP1-
overexpressing HeLa cells. Two million cells were injected
subcutaneously into the ﬂanks of non-obese diabetic-severe
combined immunodeﬁciency mice (n= 12 tumors per cohort).
The experiment was terminated when any mouse reached pre-set
welfare limits. LARP1 overexpression resulted in signiﬁcantly more
rapid tumor growth, with a mean ﬁnal tumor volume of 162.8
mm3, compared to 51.0 mm3 in the control group. These results
show that LARP1 overexpression increases tumorigenicity
(Figure 7a). Similar results were obtained when the experiment
Figure 6. LARP1 promotes invasion and anchorage-independent growth. (a) Invasion assay in HeLa cells stably transfected with pTrex-LARP1
and pTrex-LacZ cells or (b) with pooled siRNA to LARP1 and non-targeting control. Graphs are counts of the number of invasive cells per cm2.
Representative images of DAPI-stained invasive cells are shown (scale bars, 250 μm). (c) Anchorage-independent growth assay using ultra-low
attachment plates in HeLa cells stably transfected with pTrex-LARP1 and pTrex-LacZ. Representative images of spherosomes (scale bars,
200 μm). (d) Number of colonies generated by dissociated spherosomes plated in adherent conditions. Scale bars, 2 cm. Experiments were
performed ⩾ 3 times; data are mean± s.e.m. *P⩽0.05 and **P⩽0.001.
LARP1 in cancer progression
M Mura et al
5031
© 2015 Macmillan Publishers Limited Oncogene (2015) 5025 – 5036
was repeated in BALB/c nude mice (Supplementary Figure S9a).
We subjected xenograft tumors from non-obese diabetic-severe
combined immunodeﬁciency mice to further histological exam-
ination. Ki67 positivity was ⩾ 90% in both LARP1-overexpressing
tumors and controls (Supplementary Figure S9b), as has been
previously demonstrated for HeLa xenografts.28 There was no
signiﬁcant difference in intratumoral vessel density between
tumors, as determined by CD31 staining, but there was a trend
toward increased vascularity at the periphery of LARP1-
overexpressing tumors (Supplementary Figure 9c). Immunohisto-
chemistry staining showed that the level of mTOR was increased
in LARP1-overexpressing xenograft tumors (Figure 7b). To further
validate this result, total protein was extracted from frozen tumor
and expression of mTOR measured by western blotting, where it
was conﬁrmed to have increased (Figure 7c).
DISCUSSION
RBPs contribute to the post-transcriptional regulation of gene
expression by binding and regulating the stability of target
Figure 7. LARP1 promotes tumor progression in vivo and is associated with increased mTOR expression in xenograft tumors. (a) Two million
HeLa pTrex-LacZ or pTrex-LARP1 cells were injected subcutaneously into the posterior ﬂank of non-obese diabetic-severe combined
immunodeﬁciency mice and tumor volume was monitored by caliper measurements. Representative mice from each cohort are shown (scale
bars, 1 cm). (b) Immunohistochemistry analysis of mTOR protein level in xenograft tumors (scale bars, 200 μm). (c) Relative quantiﬁcation of
mTOR protein levels in xenograft tumors generated from pTrex-LacZ and pTrex-LARP1 cells with a corresponding western blot shown
(sequential numbers represent tumors from different mice). Data are means± s.e.m. *P⩽0.05.
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mRNAs.29,30 We show here using RNA-immunoprecipitation, exon-
microarray and bioinformatic analysis that the RBP LARP1 is
complexed to an interactome of over 3000 mRNAs, many of which
are known to be dysregulated in cancer. To explore the effect of
LARP1 interaction on these mRNAs, we examined the relationship
between LARP1 and mTOR, one member of the LARP1 interactome.
We showed that an association with LARP1 promotes the stability
of mTOR messenger RNA leading to enhancement of its protein
expression and that this effect is mediated through the 3′UTR of
mTOR mRNA. Loss of LARP1 causes a reduction in mTOR protein as
well as downstream members of the mTORC1 signaling pathway,
including phosphorylated proteins such as RPS6 and 4E-BP1.
Although mTOR is critical regulator of normal processes within
the cell, such as metabolism and growth, it is a central component
of the PI3K/AKT/mTOR signaling pathway which is frequently
dysregulated in cancer.27 Increased expression of mTOR and its
downstream signaling pathways has previously been shown to
lead directly to tumorigenesis and selective inhibitors of mTOR
protein are now in use as cancer treatments.31 However, relatively
little is known about the post-transcriptional regulation of
mTOR.32,33 Although 3′UTRs are generically known to contain
cis-elements, which determine RBP-complex binding or micro-RNA
pairing,26 the precise nature of (and other components involved
in) the binding mechanism between LARP1 and mTOR is as yet
undetermined. LARP1 has previously been reported to be a
binding partner of the 3′-associated protein PABP and to exist in
complex with polyadenylated mRNA.12–14,34 PABP itself plays a
fundamental role in the stability and translation of mRNA by both
protecting the transcript from deadenylation and facilitating its
circularization.35,36 It is possible that LARP1 acts synergistically
with PABP perhaps by strengthening the interaction between
PABP and the 5′-cap components. This would support previous
research showing LARP1 protein is in complex with eIF4E and
eIF4G, in addition to PABP.34
Recently, in benign cell lines, LARP1 has been reported to
regulate 5′-TOP mRNA transcripts by stabilizing them and/or
enhancing their translation.13,14 Consistent with these ﬁndings, we
identiﬁed a number of 5′-TOP transcripts within the HeLa-LARP1
interactome. However, we show that, in HeLa at least, LARP1 does
not associate with all TOP mRNAs and some, such as RPS6, were
absent from the interactome. In our hands, LARP1 binds a wider
population of mRNAs, such as those involved in focal adhesion,
actin remodeling and extracellular matrix interactions, as well as
components of the VEGF and MAPK signaling pathways. This
implies that in cancer cells the LARP1 interactome is more
extensive than has been described previously.
Overall, we see that LARP1 is involved in modulating the
tumorigenicity of cancer cells and its overexpression drives tumor
progression in vivo. Although mTOR overexpression has been
shown to contribute to oncogenic transformation, it is likely that
LARP1 affects tumorigenicity via an effect on multiple signaling
pathways. In addition, by affecting key proteins such as P-RPS6
and P-4E-BP1 downstream of the mTORC1 signaling pathway,
LARP1 indirectly affects global protein synthesis.14,34
It is probable that RBPs like LARP1 do not act alone but work
collectively with other RNA-associated factors to stabilize or
destabilize its target mRNAs. Although we show the net effect of
LARP1 in these cancer cells is to stabilize and enrich protein
expression, conﬁrmed here at transcript level with mTOR, it is
possible that LARP1 destabilizes some transcripts while stabilizing
others. This has been observed with other RBPs such as HuR,
which plays a predominant role in mRNA stability but can also
promote the decay of p16INK4 and c-Myc.23,37,38 In Arabidopsis,
the net effect of LARP1 is to cause mRNA decay in response to cell
stress, via an interaction with the 5′–3′ exonuclease
enzyme exoribonuclease 4 (XRN4).39 In human embryonic kidney
cells the net effect of LARP1 is also positive, stabilizing TOP mRNAs
and ensuring the ongoing manufacture of proteins required for
growth-related ribosome biogenesis. This implies that the function
of LARP1, either as an activator or repressor of mRNA stability is
context speciﬁc.
In non-small cell lung and cervical cancer, higher levels of
LARP1 protein correlate with tumor progression and adverse
survival. Cervical cancer is known to be a genomically complex
tumor with considerable intratumoral heterogeneity.40 Our ﬁnd-
ings support the importance of post-transcriptional regulation in
the progression of cervical cancer and demonstrate that, through
its regulation of target mRNAs such as mTOR, LARP1 plays a
central role. Two independent reports have shown that LARP1 is
phosphorylated by mTOR and is an important effector of mTORC1
signaling.15,16 We speculate that LARP1 regulates the activity of
mTORC1 in a positive-feedback loop by being a downstream
substrate of mTORC1 and simultaneously regulating the stability
of its mRNA transcript.
As LARP1 is highly expressed in multiple epithelial cancer types,
its upregulation may represent a common feature of tumor
progression. RBPs like LARP1, which selectively regulate the
stability of multiple mRNA transcripts, are exciting potential
therapeutic targets, as their inhibition could simultaneously target
multiple oncogenic pathways.5 By acting at a point of conver-
gence of multiple cancer signaling cascades, LARP1 is an
important post-transcriptional regulator of cancer progression
and may prove to be a target for therapeutic intervention.
MATERIALS AND METHODS
Oncomine data analysis
Expression data for LARP1 were downloaded from Oncomine.20 Fold
change was calculated as median-centered intensity of each cancer sample
divided by the mean of non-cancer samples.
Immunohistochemistry
Two cervical cancer tissue arrays were obtained commercially from US
Biomax (Rockville, MD, USA) were stained as described by Shi et al.41
Cytoplasmic scores were calculated as a sum of staining intensity (0–3,
with 3 being most intense) multiplied by the percentage of stained cells
(0–100%), giving a range of 0–300. All scorings were performed ‘blind’ by
consultant clinical histopathologists. All images were captured using a
Nikon Eclipse ME600 (Nikon, Kingston Upon Thames, UK) (antibodies:
LARP1-SDIX, mTOR-CST, Ki67-Leica and CD31-NovusBiological).
RNA from patient samples
RNA from cervical cancer tissue samples were obtained from the Imperial
College Healthcare Tissue Bank. Samples were collected under the
College’s Human Tissue Authority license approved by the local Research
and Ethics Committee and the Tissue Management Committee.
Cell culture
The identity of cervical cancer (HeLa) and non-small cell lung cancer (PC9)
cell lines was conﬁrmed by genotyping (Genetica DNA Laboratories,
Burlington, NC, USA). Cells were cultured with complete Dulbecco's
Modiﬁed Eagle's medium (DMEM) (HeLa) or RPMI-1640 (PC9) in a 5% CO2
atmosphere, at 37 °C.
RNA immunoprecipitation and expression array analysis
RNA was immunoprecipitated with 15-μg LARP1 polyclonal antibody
(SDIX) or IgG isotype control (CST) following the method described by
Keene et al.42 RNA was extracted with Trizol (Life Technologies, Carlsbad,
CA, USA) and puriﬁed with RNA clean-up and concentration micro kit
(Norgen Biotek, Thorold, ON, Canada). Input and immunoprecipitated RNA
obtained from four independent experiments were analyzed in duplicate
on Agilent exon arrays by Oxford Gene Technology (Begbroke, UK). RNA
was quality assessed in a bioanalyser with the RNA 6000 pico kit (Agilent
Technologies, Santa Clara, CA, USA), labeled with Agilent low-input
QuickAmp WT labeling kit (Agilent Technologies) and hybridized to the
Agilent 4x180 K Exon arrays (Agilent Technologies) as per manufacturer
protocols.
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RIP-Chip data analysis
Data from Exon arrays were normalized in Agilent’s Feature Extraction
software (Agilent Technologies), according to the manufacturer’s instruc-
tions. The normalized log2 intensity ratios of RIP fraction over total RNA
were obtained for each replicate array. Statistical signiﬁcance of
enrichment was estimated by calculating empirical Bayes moderated
t-statistics using Linear Models for Microarray Data (LIMMA),43 as
implemented in Bioconductor (http://www.bioconductor.org). Benjamini-
Hochberg correction was used to adjust P-values for multiple testing.
Probes with a fold change 42 and an adjusted P-value o1 × 10− 4 were
considered to be signiﬁcantly enriched in the immuno-precipitated RNA,
and members of the LARP1 interactome.
Actinomycin-D treatment
HeLa cells were transfected with control siRNA (GGUCCGGCUCCCCCAA
AUG) or a mixture of two different LARP1-targeting siRNA (siRNA1-
AGACUCAAGCCAGACAUCA and siRNA2- GAAUGGAGAUGAGGAUUGC) as
described earlier.6 Each siRNA targets both LARP1 isoforms (150 and
130 kD).44 Forty-eight hours after the ﬁrst transfection, cells were treated
with 5 μg/ml of actinomycin-D for up to 4 h. RNA was extracted and
processed as described below.
UTRs luciferase assay
mTOR 3′UTR and its relative control plasmid with ﬁreﬂy-luciferase reporter
system were purchased from Origene Technologies (Rockville, MD, USA).
mTOR 5′UTR (GGGGCCTGAAGCGGCGGTACCGGTGCTGGCGGCGGCAGCTGA
GGCCTTGGCCGAAGCCGCGCGAACCTCAGGGCAAG) was cloned into the
pLightSwitch_5UTR (SwitchGear Genomics, Carlsbad, CA, USA) with renilla
luciferase reporter system. Beta actin 5′UTR was used as a control. HeLa
cells were transfected with plasmid DNA using Effectene (Qiagen, Limburg,
Netherlands) according to the manufacturer’s instructions, following
transient siRNA knockdown of LARP1. Renilla and ﬁreﬂy control vectors
were co-transfected respectively with the ﬁreﬂy and renilla-UTR vectors in a
ratio of 25:75 to take into account the efﬁciency of transfection and cell
numbers. Luciferase activity of the construct carrying either the 5′ or 3′ UTR
was normalized to the relative control construct. Luciferase activity was
assessed with the Dual-Luciferase Reporter assay system (Promega,
Madison, WI, USA). Luminescence was measured using the Lumistar
OPTIMA plate reader (BMG Labtech, Aylesbury, UK).
Q-RT–PCR
RNA from patients and from immunoprecipitated samples was retro-
transcribed with SensiScript RT kit (Qiagen). RNA from cells treated with
actinomycin-D was extracted with RNeasy plus mini kit (Qiagen) and
retrotranscribed using MMLV reverse transcriptase (Promega). RT–PCR was
performed with TaqMan assay primers and probes (Applied Biosystems,
Life Technologies), and run on the ABI 7900HT. 18S rRNA was used as
control reference as it remained stable after LARP1 knockdown and was
not affected by actinomycin-D treatment. Relative mRNA levels were
calculated using the ΔΔCt formula. The fold enrichment of immunopre-
cipitated RNA was measured by comparing the Ct values of LARP1-IP
fraction to the IgG-IP fraction and normalized using the ΔΔCt formula
(primers: LARP1-HS00369275_S1, AKT1-HS00178289_m1, AKT2-
HS01086102_m1, MAPK11-HS011558727_gH, MAPK12-HS00268060_m1,
MAPK14-HS01051152_m1, TWIST1-HS00361152_m1, MTOR-HS01042412_m1
and 18-HS99999901_s1).
Protein extraction and western blotting
Western blotting was performed as previously described.34 Xenograft
tumors were homogenized with a polypropylene pellet pestle (Sigma-
Aldrich, St Louis, MO, USA) and lysates cleared using centrifugation. Clean-
Blot IP detection reagent (Pierce Biotechnology, Rockford, IL, USA) was
used for detection of immunoprecipitated LARP1 (antibodies: LARP1-SDIX,
mTOR-CST, RPS6-CST, RPS6-p240/244-CST, 4EBP1-CST, 4EBP-P37/46-CST
and HSP60-ABCAM).
Reverse-phase protein array
HeLa cells were transfected with control non-targeting or a mixture of two
different LARP1-targeting siRNAs as described earlier.34 Samples were
analyzed by the MD Anderson Cancer Center Proteomic Facility (Houston,
Texas, USA), as previously described by Tibes et al.45 Normalized Log2 intensity
of ﬂuorescence was used to calculate changes in protein expression. A change
of 10% relative to control was considered to be functionally relevant.
Stable clone generation
LARP1 cDNA was obtained from the pOTB7-LARP1 vector (Life Technol-
ogies). PCR primers were designed for gene ampliﬁcation with the addition
of attB sites (forward: 5′-Ggggacaagtttgtacaaaaaagcaggcttcgaccatgg
GTCAAAGAGGCCTCCTTTCC-3′ and reverse: 5′-Ggggaccactttgtacaagaaa
gctgggtcctagctaTTTCACTTTCCCAAAGTCTG-3′). The PCR product attB-
LARP1 was cloned into the Gateway Technology System expression
plasmid pTrex-DEST30 according to the manufacturer’s instructions (Life
Technologies). HeLa and PC9 cells were transfected with 1 μg of pTrex-
LARP1 and pTrex-LacZ using Effectene (Qiagen) according to the
manufacturer’s instructions. To generate stable clones, 48 h after transfec-
tion HeLa cells were cultured in DMEM containing Geneticin (Life
Technologies) at a 700 μg/ml ﬁnal concentration until at least 200
individual colonies were formed. Pooled clones were used for subsequent
experiments.
Migration assay
pTrex-LARP1 and pTrex-LacZ HeLa cell-derived stable clones or pTrex-
LARP1 and pTrex-LacZ transiently transfected PC9 cells were cultured to
conﬂuence and serum-starved overnight (1% Fetal Calf Serum (FCS))
before a scratch was applied with a pipette tip. Pictures were acquired with
a Nikon Eclipse TE-2000U microscope and surface area of the open wound
was measured using ImageJ (http://imagej.nih.gov/ij).
Invasion assay
Approximately 1 × 105 cells in serum-free medium were plated in the
upper insert of a BD BioCoat Matrigel Invasion Chamber (BD Biosciences)
with 8-μM pores, while the bottom well was ﬁlled with medium
supplemented with 10% FCS. After 24-h incubation, non-invasive cells
were removed from the upper surface of the membrane. Cells in the lower
surface of the membrane were ﬁxed with ice-cold methanol and stained
with 4′,6-diamidino-2-phenylindole (DAPI). Images were acquired with
Leica 500 confocal microscope and processed with Leica LAS AF lite
software (Leica Camera AG, Solms, Germany). DAPI-stained nuclei were
counted with ImageJ.
Anchorage-independent growth assay
Approximately 1 × 103/ml cells were seeded in ultra-low attachment
surface 96-well plates (Corning Incorporated, Corning, NY, USA). Single-
cell suspensions were incubated in complete medium for 2.5 weeks.
Spherosomes were counted and then dissociated with trypsin to a single-
cell suspension. Colonies formed after 3 weeks were ﬁxed with ice-cold
methanol and stained with 0.5% crystal violet. Plates were photographed
using a GE ImageQuant LAS 4000 (GE Healthcare Life Sciences,
Little Chalfont, UK) and colonies were counted using ImageJ software.
MTT enzymatic conversion assay
Cells were cultured at 37 °C and labeled with 10 μl of 3-(4,5-Dimethylthia-
zol-2-yl)-2,5-Diphenyltetrazolium Bromide MTT (Sigma) at 3 mg/ml for 2 h.
The precipitate was solubilized overnight with 10% SDS in 0.01-M HCl.
Absorbance at 562 nm was recorded using an OPTImax microplate reader
(Molecular Devices, Winnersh, UK).
In vivo work
All animal experiments were performed by licensed investigators in
accordance with the United Kingdom Home Ofﬁce Guidance on the
Operation of the Animal (Scientiﬁc Procedures) Act 1986 and within the
newly published guidelines for the welfare and use of animals in cancer
research.46 Female non-obese diabetic-severe combined immunodeﬁciency
or BALB/c nude mice (aged 6–8 weeks; Charles River Laboratories,
Wilmington, MA, USA) were used. HeLa pTrex-LARP1 and pTrex-LacZ cells
(2× 106) were injected subcutaneously on the ﬂanks of mice (at least ﬁve
per cohort). Tumor dimensions were measured continuously using a caliper
and tumor volumes were calculated by the equation: volume= (π/6) × a×
b× c, where a, b and c represent three orthogonal axes of the tumor. The
experiment was terminated before any mouse reached pre-set welfare
limits. Tumors were collected and either immediately snap-frozen and
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preserved at − 80 °C, or ﬁxed in 10% formalin for 48 h before parafﬁn
embedding and sectioning.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software
(GraphPad Software, San Diego, CA, USA), using Student's t-test unless
otherwise stated in the Materials and methods section. S.e.m. was used as
the measure of variation from the population mean in all our experiments;
degree of statistical signiﬁcance was represented using asterisks: P⩽ 0.05
(*), P⩽ 0.001 (**) and P⩽ 0.0001 (***).
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